Cover Image
市場調查報告書

格林-巴利症候群:開發平台分析

Guillain-Barre Syndrome - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 332891
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
格林-巴利症候群:開發平台分析 Guillain-Barre Syndrome - Pipeline Review, H2 2016
出版日期: 2016年10月29日 內容資訊: 英文 48 Pages
簡介

為了所謂格林-巴利症候群 (GBS) ,體內的免疫系統攻擊末梢神經系統的一部分,最初雖然有程度的差但是腳的肌肉無力和刺人痛地做的感覺呈現。大量地的情況,手臂和上半身左右對稱性的肌肉無力和感覺異常蔓延。這樣的症狀,到特定的肌肉完全變得不擺動續,厲害的時候也有幾乎全身麻痺了的事。作為危險因素流感·病毒,霉漿菌屬肺炎,何杰金氏淋巴瘤,愛潑斯坦·酒吧·病毒等舉出(舉行)。

本報告提供全球格林-巴利症候群的開發中產品的開發情形相關分析,送交調查了開發中產品的最新趨勢,及臨床實驗的各階段有的產品的一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發的發展情形),最新的產業趨勢等的結果。

簡介

  • 調查範圍
  • 格林-巴利症候群 概要

治療藥的開發

  • 開發中產品;格林-巴利症候群;概要
  • 開發中產品;格林-巴利症候群;比較分析

在企業正在開發的治療藥

在大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

在企業開發中的產品

在大學/機關研究中的產品

治療藥開發作的企業

治療藥的評估

  • 單劑產品
  • 按標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Coversin
  • eculizumab
  • immune globulin (human)
  • immune globulin (human)
  • Peptide for Cholera and Guillain-Barre Syndrome

最近的開發平台趨勢

暫停中的計劃

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8599IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Guillain-Barre Syndrome - Pipeline Review, H2 2016, provides an overview of the Guillain-Barre Syndrome (Central Nervous System) pipeline landscape.

Guillain-Barre syndrome (GBS) is a disorder in which the body's immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include varying degrees of weakness or tingling sensations in the legs. In many instances the symmetrical weakness and abnormal sensations spread to the arms and upper body. These symptoms can increase in intensity until certain muscles cannot be used at all and, when severe, the person is almost totally paralyzed. Risk Factors include influenza virus, mycoplasma pneumonia, Hodgkin's lymphoma and Epstein-Barr virus.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Guillain-Barre Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Guillain-Barre Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Guillain-Barre Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Guillain-Barre Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 2 and 3 respectively for Similarly, the Universities portfolio in Phase III and Discovery stages comprises 1 and 1 molecules, respectively for Guillain-Barre Syndrome.

Guillain-Barre Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Guillain-Barre Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Guillain-Barre Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Guillain-Barre Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Guillain-Barre Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Guillain-Barre Syndrome (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Guillain-Barre Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Guillain-Barre Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Guillain-Barre Syndrome Overview
  • Therapeutics Development
    • Pipeline Products for Guillain-Barre Syndrome - Overview
    • Pipeline Products for Guillain-Barre Syndrome - Comparative Analysis
  • Guillain-Barre Syndrome - Therapeutics under Development by Companies
  • Guillain-Barre Syndrome - Therapeutics under Investigation by Universities/Institutes
  • Guillain-Barre Syndrome - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Guillain-Barre Syndrome - Products under Development by Companies
  • Guillain-Barre Syndrome - Products under Investigation by Universities/Institutes
  • Guillain-Barre Syndrome - Companies Involved in Therapeutics Development
    • Akari Therapeutics, Plc
    • CuraVac, Inc.
    • Hansa Medical AB
    • Regenesance BV
    • Vitality Biopharma Inc
  • Guillain-Barre Syndrome - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Coversin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation, Central Nervous System and Autoimmune Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit C6 for Guillain-Barre Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize CB1 and CB2 for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Guillain-Barre Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Guillain-Barre Syndrome - Dormant Projects
  • Guillain-Barre Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • May 23, 2016: Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain-Barre Syndrome
      • May 12, 2016: Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Guillain-Barre Syndrome
      • Jan 29, 2016: Akari Therapeutics Receives Approval From the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial
      • Jan 05, 2016: Akari Therapeutics Announces Additional Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays
      • Dec 07, 2015: Akari Therapeutics Announces Update From Non-Human Primate Safety Study at International PNH Interest Group 10th Annual Scientific Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Guillain-Barre Syndrome, H2 2016
  • Number of Products under Development for Guillain-Barre Syndrome - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Guillain-Barre Syndrome - Pipeline by Akari Therapeutics, Plc, H2 2016
  • Guillain-Barre Syndrome - Pipeline by CuraVac, Inc., H2 2016
  • Guillain-Barre Syndrome - Pipeline by Hansa Medical AB, H2 2016
  • Guillain-Barre Syndrome - Pipeline by Regenesance BV, H2 2016
  • Guillain-Barre Syndrome - Pipeline by Vitality Biopharma Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Guillain-Barre Syndrome - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Guillain-Barre Syndrome, H2 2016
  • Number of Products under Development for Guillain-Barre Syndrome - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top